Peptides Are Everywhere!
In a Nutshell
Retatrutide is a promising triple agonist in phase 3 trials that simultaneously targets GLP-1, GIP, and glucagon receptors for appetite suppression, glucose control, and increased energy expenditure, but it carries early signals of potential nerve damage and should not be used until more safety data exists. GHK-Cu and BPC-157 lack meaningful human evidence and are similarly cautioned against due to unknown purity and safety risks. The core message is that peptides should never precede foundational lifestyle work—optimizing nutrition, training, sleep, and glucose control must come first, with medications like Mounjaro considered only afterward under medical supervision.
These notes were generated by AI and may contain inaccuracies.
Retatrutide is a legitimate triple receptor agonist currently generating significant attention. It activates three mechanisms simultaneously: GLP-1 (similar to Ozempic), GIP (similar to Mounjaro or tirzepatide), and glucagon receptors. This combination reduces appetite, improves glucose control, and increases energy expenditure at the same time. The glucagon component is responsible for the energy expenditure increase. Retatrutide is currently in phase three clinical trials, meaning it is being tested in large human populations before potential FDA approval.
Retatrutide stands out among current peptides as particularly worth monitoring due to its novel mechanism profile. While it is possible to obtain it before approval, there are reports of people already trying it, though a signal regarding potential nerve damage exists. Waiting for more safety data is recommended.
GHK-Cu is a copper-binding peptide widely discussed for skin repair, collagen remodeling, and wound healing applications. The research supporting GHK-Cu is primarily preclinical, consisting mainly of animal studies and laboratory work with limited human evidence available. While the underlying science is interesting, GHK-Cu does not have the same level of development or evidence as retatrutide.
BPC-157 is popular in recovery and biohacking communities for tendon repair, gut health, and inflammation management. The enthusiasm surrounding BPC-157 is substantial, and interesting mechanistic information exists, but the evidence is almost entirely animal data with mechanistic speculation rather than high-quality human trials.
Sign in to read the full notes
Get access to AI-generated notes, topic timestamps, and more.